These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis. Gotlib J; Schwaab J; Shomali W; George TI; Radia DH; Castells M; Carter MC; Hartmann K; Álvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Hoermann G; Sperr WR; Elberink HO; Siebenhaar F; Butterfield JH; Ustun C; Zanotti R; Triggiani M; Schwartz LB; Lyons JJ; Orfao A; Sotlar K; Horny HP; Arock M; Metcalfe DD; Akin C; Lübke J; Valent P; Reiter A J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2025-2038.e1. PubMed ID: 35724948 [TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet? Akin C; Arock M; Valent P J Allergy Clin Immunol; 2022 Jun; 149(6):1912-1918. PubMed ID: 35487307 [TBL] [Abstract][Full Text] [Related]
4. Midostaurin: a magic bullet that blocks mast cell expansion and activation. Valent P; Akin C; Hartmann K; George TI; Sotlar K; Peter B; Gleixner KV; Blatt K; Sperr WR; Manley PW; Hermine O; Kluin-Nelemans HC; Arock M; Horny HP; Reiter A; Gotlib J Ann Oncol; 2017 Oct; 28(10):2367-2376. PubMed ID: 28945834 [TBL] [Abstract][Full Text] [Related]
5. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors. Shomali W; Gotlib J Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174 [TBL] [Abstract][Full Text] [Related]
6. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. Aichberger KJ; Gleixner KV; Mirkina I; Cerny-Reiterer S; Peter B; Ferenc V; Kneidinger M; Baumgartner C; Mayerhofer M; Gruze A; Pickl WF; Sillaber C; Valent P Blood; 2009 Dec; 114(26):5342-51. PubMed ID: 19850739 [TBL] [Abstract][Full Text] [Related]
7. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Gleixner KV; Mayerhofer M; Sonneck K; Gruze A; Samorapoompichit P; Baumgartner C; Lee FY; Aichberger KJ; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P Haematologica; 2007 Nov; 92(11):1451-9. PubMed ID: 18024392 [TBL] [Abstract][Full Text] [Related]
8. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801 [TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis. Lyberg K; Ali HA; Grootens J; Kjellander M; Tirfing M; Arock M; Hägglund H; Nilsson G; Ungerstedt J Oncotarget; 2017 Feb; 8(6):9647-9659. PubMed ID: 28038453 [TBL] [Abstract][Full Text] [Related]
10. Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT. Bandara G; Muñoz-Cano R; Tobío A; Yin Y; Komarow HD; Desai A; Metcalfe DD; Olivera A Front Immunol; 2018; 9():631. PubMed ID: 29643855 [TBL] [Abstract][Full Text] [Related]
11. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. Hartmann K; Gotlib J; Akin C; Hermine O; Awan FT; Hexner E; Mauro MJ; Menssen HD; Redhu S; Knoll S; Sotlar K; George TI; Horny HP; Valent P; Reiter A; Kluin-Nelemans HC J Allergy Clin Immunol; 2020 Aug; 146(2):356-366.e4. PubMed ID: 32437738 [TBL] [Abstract][Full Text] [Related]
12. Kit Mutations: New Insights and Diagnostic Value. Falchi L; Verstovsek S Immunol Allergy Clin North Am; 2018 Aug; 38(3):411-428. PubMed ID: 30007460 [TBL] [Abstract][Full Text] [Related]